%0 Journal Article
%A Handke, Analena
%A Kesch, Claudia
%A Fendler, Wolfgang Peter
%A Telli, Tugce
%A Liu, Yang
%A Hakansson, Alexander
%A Davicioni, Elai
%A Hughes, Jason
%A Song, Hong
%A Lueckerath, Katharina
%A Herrmann, Ken
%A Hadaschik, Boris
%A Seifert, Robert
%T Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy.
%J Journal for ImmunoTherapy of Cancer
%V 11
%N 10
%@ 2051-1426
%C London
%I BioMed Central
%M DKFZ-2023-02119
%P e007354
%D 2023
%X 177Lu-PSMA ([177Lu]Lutetium-PSMA-617) therapy is an effective treatment option for patients with prostate specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer, but still shows a non-responder rate of approximately 30
%K Prostatic Neoplasms (Other)
%K Radiotherapy (Other)
%K Tumor Biomarkers (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37857524
%R 10.1136/jitc-2023-007354
%U https://inrepo02.dkfz.de/record/284823